Summary
Osteosarcoma treatment remains chemotherapy-dominated, with standard care combining surgery, chemotherapy, and, in selected cases, radiation therapy.
The market continues to face significant unmet medical needs, with few treatments specifically approved for osteosarcoma. KHAPZORY is FDA-approved in the United States, while MEPACT is approved in the European Union, underscoring the need for more effective disease-specific therapies.
The osteosarcoma drug pipeline is expanding, with candidates such as OST-HER2 (OS Therapies), DANYELZA (naxitamab-gqgk) (SERB Pharmaceutical), Vactosertib (MedPacto), Risvutatug rezetecan (GSK), Olaparib With Ceralasertib ...